Publication | Closed Access

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

Hematological MalignancyMedicineImmunologyHematologyAutoimmunityPhase 2ImmunotherapyOncologyRadiation OncologyAdult T-cell Leukemia-lymphomaRefractory Multiple MyelomaHealth Sciences